Tenax Therapeutics Stock Today
| TENX Stock | USD 4.92 0.07 1.44% |
Performance7 of 100
| Odds Of DistressOver 72
|
Tenax Therapeutics is trading at 4.92 as of the 22nd of November 2024; that is 1.44 percent increase since the beginning of the trading day. The stock's open price was 4.85. Tenax Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Tenax Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of April 2023 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of January 1997 | Category Healthcare | Classification Health Care |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. The company has 3.41 M outstanding shares of which 105.76 K shares are at this time shorted by private and institutional investors with about 1.46 trading days to cover. More on Tenax Therapeutics
Moving against Tenax Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tenax Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Christopher Giordano | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsTenax Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tenax Therapeutics' financial leverage. It provides some insight into what part of Tenax Therapeutics' total assets is financed by creditors.
| |||||
Tenax Therapeutics (TENX) is traded on NASDAQ Exchange in USA. It is located in 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 and employs 5 people. Tenax Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.53 M. Tenax Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.41 M outstanding shares of which 105.76 K shares are at this time shorted by private and institutional investors with about 1.46 trading days to cover.
Tenax Therapeutics currently holds about 7.23 M in cash with (5.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Tenax Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Tenax Therapeutics is $16.53 Million. 30% of Tenax Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Tenax Ownership Details
Tenax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Hanson Mcclain Inc | 2024-09-30 | 1.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Fmr Inc | 2024-09-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 | |
| Tucker Asset Management Llc | 2024-06-30 | 0.0 | |
| Bvf Inc | 2024-09-30 | 339.5 K | |
| Vivo Capital, Llc | 2024-09-30 | 208.3 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 21 K | |
| Geode Capital Management, Llc | 2024-06-30 | 11 K | |
| Qube Research & Technologies | 2024-06-30 | 4.4 K | |
| Ubs Group Ag | 2024-06-30 | 1.5 K |
Tenax Therapeutics Historical Income Statement
Tenax Stock Against Markets
Tenax Therapeutics Corporate Management
| Doug Randall | Executive VP of Commercial and Bus. Operations | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Nancy Hecox | Gen Affairs | Profile | |
| Esq CPA | Interim Officer | Profile |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.